PET Scan: Nuclear Medicine Imaging in Myositis

Overview

Journal Curr Rheumatol Rep

Publisher Current Science

Specialty Rheumatology

Date 2019 Nov 23

PMID 31754890

Citations 5

Authors

Albert Selva-OCallaghan

Albert Gil-Vila

Marc Simo-Perdigo

Ernesto Trallero-Araguas

Marcelo Alvarado-Cardenas

Iago Pinal-Fernandez

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: Positron emission tomography (PET) combined with computed tomography (CT) has proven useful as a cancer screening technique in patients with inflammatory myopathy, mainly dermatomyositis. In this review, we focus on advances in this direction and other potential applications of PET/CT in patients with inflammatory myopathy.

Recent Findings: Cancer screening by PET/CT seems suitable and cost-effective in patients with myositis. It has also shown value as a hybrid technique for diagnosing myositis versus controls and could be of interest for differentiating between polymyositis and sporadic inclusion body myositis. Quantification of muscle activity by PET/CT seems reliable. Preliminary data suggest that it could also be used to diagnose and measure the activity of the disease in the lung. PET/CT should be in the toolbox of physicians managing patients with myositis. The multiple applications of PET/CT include its value for cancer screening, measuring the activity of the disease in muscle, and helping to differentiate between myositis phenotypes. The possibility to diagnose and monitor inflammatory lung activity remains to be demonstrated in well-designed studies.

Citing Articles

Imaging in myositis: MRI or F-FDG PET/CT?.

Ilgen U, Emmungil H Clin Rheumatol. 2022; 41(7):2253-2254.

PMID: 35357632 DOI: 10.1007/s10067-022-06141-y.

Cancer screening in idiopathic inflammatory myopathies: Ten years experience from a single center.

Trallero-Araguas E, Gil-Vila A, Martinez-Gomez X, Pinal-Fernandez I, Alvarado-Cardenas M, Simo-Perdigo M Semin Arthritis Rheum. 2022; 53:151940.

PMID: 35051890 PMC: 11678788. DOI: 10.1016/j.semarthrit.2021.12.008.

Radiological Characteristics of Patients With Anti-MDA5-Antibody-Positive Dermatomyositis in F-FDG PET/CT: A Pilot Study.

Cao H, Liang J, Xu D, Liu Y, Yao Y, Sun Y Front Med (Lausanne). 2021; 8:779272.

PMID: 34881270 PMC: 8645547. DOI: 10.3389/fmed.2021.779272.

Clinical Value of F-FDG PET/CT Scan and Cytokine Profiles in Secondary Hemophagocytic Lymphohistiocytosis in Idiopathic Inflammatory Myopathy Patients: A Pilot Study.

Liang J, Cao H, Wu B, Liu Y, He Y, Xu B Front Immunol. 2021; 12:745211.

PMID: 34867971 PMC: 8636988. DOI: 10.3389/fimmu.2021.745211.

Novel Muscle Imaging in Inflammatory Rheumatic Diseases-A Focus on Ultrasound Shear Wave Elastography and Quantitative MRI.

Farrow M, Biglands J, Alfuraih A, Wakefield R, Tan A Front Med (Lausanne). 2020; 7:434.

PMID: 32903395 PMC: 7434835. DOI: 10.3389/fmed.2020.00434.

References

van de Vlekkert J, Maas M, Hoogendijk J, de Visser M, van Schaik I . Combining MRI and muscle biopsy improves diagnostic accuracy in subacute-onset idiopathic inflammatory myopathy. Muscle Nerve. 2014; 51(2):253-8. DOI: 10.1002/mus.24307. View

Tateyama M, Fujihara K, Misu T, Arai A, Kaneta T, Aoki M . Clinical values of FDG PET in polymyositis and dermatomyositis syndromes: imaging of skeletal muscle inflammation. BMJ Open. 2015; 5(1):e006763. PMC: 4298089. DOI: 10.1136/bmjopen-2014-006763. View

Sun L, Dong Y, Zhang N, Lv X, Chen Q, Wei W . [F]Fluorodeoxyglucose positron emission tomography/computed tomography for diagnosing polymyositis/dermatomyositis. Exp Ther Med. 2018; 15(6):5023-5028. PMC: 5958694. DOI: 10.3892/etm.2018.6066. View

Buchbinder R, Forbes A, Hall S, Dennett X, Giles G . Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study. Ann Intern Med. 2001; 134(12):1087-95. DOI: 10.7326/0003-4819-134-12-200106190-00008. View

Uehara T, Takeno M, Hama M, Yoshimi R, Suda A, Ihata A . Deep-inspiration breath-hold 18F-FDG-PET/CT is useful for assessment of connective tissue disease associated interstitial pneumonia. Mod Rheumatol. 2015; 26(1):121-7. DOI: 10.3109/14397595.2015.1054099. View

Basu S, Alavi A . Unparalleled contribution of 18F-FDG PET to medicine over 3 decades. J Nucl Med. 2008; 49(10):17N-21N, 37N. View

Pipitone N, Versari A, Zuccoli G, Levrini G, Macchioni P, Bajocchi G . 18F-Fluorodeoxyglucose positron emission tomography for the assessment of myositis: a case series. Clin Exp Rheumatol. 2012; 30(4):570-3. View

Lilleker J, Hodgson R, Roberts M, Herholz K, Howard J, Hinz R . [18F]Florbetapir positron emission tomography: identification of muscle amyloid in inclusion body myositis and differentiation from polymyositis. Ann Rheum Dis. 2019; 78(5):657-662. PMC: 6517800. DOI: 10.1136/annrheumdis-2018-214644. View

Kundrick A, Kirby J, Ba D, Leslie D, Olsen N, Foulke G . Positron emission tomography costs less to patients than conventional screening for malignancy in dermatomyositis. Semin Arthritis Rheum. 2018; 49(1):140-144. DOI: 10.1016/j.semarthrit.2018.10.021. View

10.

Puwanant A, Isfort M, Lacomis D, Zivkovic S . Clinical spectrum of neuromuscular complications after immune checkpoint inhibition. Neuromuscul Disord. 2019; 29(2):127-133. DOI: 10.1016/j.nmd.2018.11.012. View

11.

Dong A, Bai Y, Wang Y . Focal Myositis of the Leg Presenting as Fever of Unknown Origin Detected by FDG PET/CT. Clin Nucl Med. 2018; 44(3):251-254. DOI: 10.1097/RLU.0000000000002427. View

12.

Shigematsu T, Okayama H, Hiasa G, Kazatani Y . F-Fluorodeoxyglucose Positron Emission Tomography for the Diagnosis of Myocarditis Associated With Polymyositis. Circ J. 2016; 81(1):121-122. DOI: 10.1253/circj.CJ-16-0811. View

13.

Dalakas M . Inflammatory muscle diseases. N Engl J Med. 2015; 372(18):1734-47. DOI: 10.1056/NEJMra1402225. View

14.

Qiang J, Kim W, Baibergenova A, Alhusayen R . Risk of Malignancy in Dermatomyositis and Polymyositis. J Cutan Med Surg. 2016; 21(2):131-136. DOI: 10.1177/1203475416665601. View

15.

Allenbach Y, Keraen J, Bouvier A, Jooste V, Champtiaux N, Hervier B . High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody. Brain. 2016; 139(Pt 8):2131-5. DOI: 10.1093/brain/aww054. View

16.

Albayda J, Pinal-Fernandez I, Huang W, Parks C, Paik J, Casciola-Rosen L . Antinuclear Matrix Protein 2 Autoantibodies and Edema, Muscle Disease, and Malignancy Risk in Dermatomyositis Patients. Arthritis Care Res (Hoboken). 2017; 69(11):1771-1776. PMC: 5509530. DOI: 10.1002/acr.23188. View

17.

Lloyd T, Christopher-Stine L, Pinal-Fernandez I, Tiniakou E, Petri M, Baer A . Cytosolic 5'-Nucleotidase 1A As a Target of Circulating Autoantibodies in Autoimmune Diseases. Arthritis Care Res (Hoboken). 2015; 68(1):66-71. PMC: 4887848. DOI: 10.1002/acr.22600. View

18.

Barba T, Mainbourg S, Nasser M, Lega J, Cottin V . Lung Diseases in Inflammatory Myopathies. Semin Respir Crit Care Med. 2019; 40(2):255-270. DOI: 10.1055/s-0039-1685187. View

19.

Cao H, Pan M, Kang Y, Xia Q, Li X, Zhao X . Clinical manifestations of dermatomyositis and clinically amyopathic dermatomyositis patients with positive expression of anti-melanoma differentiation-associated gene 5 antibody. Arthritis Care Res (Hoboken). 2012; 64(10):1602-10. DOI: 10.1002/acr.21728. View

20.

Pelletier-Galarneau M, Ruddy T . Molecular imaging of coronary inflammation. Trends Cardiovasc Med. 2018; 29(4):191-197. DOI: 10.1016/j.tcm.2018.08.004. View